Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast in Parkinson Disease
NCT06113640Phase 3Completed
- Start
- Nov 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of montelukast in Parkinson's disease (PD). Started Nov 2023; status: completed.
02
Drugs
montelukast
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06113640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06113640.